Comparative Pharmacology
Head-to-head clinical analysis: AKNE MYCIN versus POLYSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKNE MYCIN versus POLYSPORIN.
AKNE-MYCIN vs POLYSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-tRNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
Topical application of 2% solution twice daily to affected areas.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
None Documented
None Documented
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Category C
Category C
Topical Antibiotic
Topical Antibiotic